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Secondary prostatic neoplasms are rarely reported, and of those that are, the most common are meta-
static tumors associated with lymphoma and leukemia.1,2 This report describes a patient with metastatic
prostatic adenocarcinoma of the stomach. The patient had received subtotal gastrectomy following
deﬁnitive diagnosis. Immunohistochemical staining of the speciﬁc markers was done retrospectively to
determine the origin of the adenocarcinoma. In the future, when a secondary prostatic neoplasm is
suspected, the stomach should be considered as a possible primary tumor site.
Copyright  2013, Taiwan Urological Association. Published by Elsevier Taiwan LLC.1. Introduction
Prostate cancer is the sixth leading cause of cancer deaths
among Taiwanese men, with adenocarcinoma being the most
common type. A prostate tumor, with negative prostate-speciﬁc
antigen (PSA) staining, is speculated to originate from an adeno-
carcinoma of the gastrointestinal tract, lung, or pancreas. Second-
ary prostatic adenocarcinoma is so uncommon that other origins
are usually considered. We report a case of secondary prostate
adenocarcinoma, which originated in the stomach.2. Case report
A 60-year-old man was diagnosed with a right-side ureteral
stone, and underwent ureterolithotripsy and double-J stenting in
early October 2008. The double-J stent was removed after 1 month
follow-up in the outpatient department (OPD); residual stones
were not observed in the kidney-ureter-bladder image. During
regular follow-up examinations, the patient complained of lower
urinary tract symptoms; consequently, a ﬁne-needle biopsy of the
prostate was performed in the OPD. The pathological report
showed benign prostatic hyperplasia, and medical treatment was
maintained. Subsequently, gross hematuria developed, and the
patient’s lower urinary tract symptoms worsened (The IPSS scored
24 in the OPD records, score 3 in the ﬁrst to the fourth questions,Surgery, Department of Sur-
ber 2, Chung-Cheng 1st Road,
ciation. Published by Elsevier Taiwand score 4 in the last three questions). The patient did not report
any improvement in his symptoms in spite of treatment with
several medicines. Approximately 2 months after his ureter-
olithotripsy, the patient underwent transurethral resection of the
prostate. A PSA-negative adenocarcinoma was found in the path-
ological specimen, and then the patient was referred to our hospital
for further treatment.
Computed tomography revealed a thickened gastric wall with
irregular contours (Fig. 1), and a malignancy was highly suspected.
The patient underwent panendoscopy with tissue biopsies (Fig. 2),
and the pathological specimens revealed adenocarcinoma of the
stomach.
Further diagnostic examinations were conducted in early
December 2008. The patient’s serum PSAwas 1.959 ng/mL; awhole
body bone scan revealed multiple bony metastases; and the ﬁnd-
ings from colonoscopy were unremarkable.
In mid-December, the patient underwent subtotal gastrectomy
and B-II anastomosis, and was discharged 2 weeks later. Gastric
adenocarcinoma was proven from the specimens reserved for
pathological analysis. The hospital where the transurethral resec-
tion of the prostate was performed had reported that speciﬁc
immunohistochemical stains had been performed on the prostatic
pathology specimen, revealing negative results for the presence of
CD117, CDX2, and cytokeratin. The same stains were performed on
the gastric specimens and produced similar negative results.
Finally, mucin stain was performed, and we found a positive result
in both gastric and prostatic specimens.
During the following year, the patient received additional
adjuvant chemotherapy and was hospitalized several times due to
poor digestion and malnutrition. The patient succumbed to thisan LLC. Open access under CC BY-NC-ND license.
Fig. 1. Malignant lesion of the gastric wall as seen by computed tomography.
Fig. 2. Panendoscopy of the stomach; malignancy was suspected in areas denoted by arrows.
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and malnutrition.
3. Discussion
Secondary prostatic malignancy due to metastasis is a rare
incidental ﬁnding during surgery and has also been found during
autopsies.3 Zein et al3 reported that a survey of 6000 cancer pa-
tients described only three cases of secondary prostate tumors with
gastric adenocarcinoma as the primary source.
Adenocarcinoma may originate from the gastrointestinal tract,
prostate gland, or other glandular tissues of the body. Most sec-
ondary tumors reach the prostate by direct spread, either from the
bladder (29 cases) or rectum (5 cases). Furthermore, Bates and
Baithun4 reported that in a series of 17 prostatic metastases, the
lungs (8 cases) and pancreas (2 cases) were the sites of the primary
lesions. The appearance of prostatic adenocarcinoma (Fig. 3A and
3B) always has dirty necrosis content, with a cribiform cell pattern.
Usually, prostatic primary adenocarcinoma stains positively for PSA
(Fig. 4A), and in the absence of positive PSA staining (Fig. 4B), one
can exclude the possibility of a prostatic origin. We used mucin as
an immunohistochemical marker, which is positive in prostaticFig. 3. (A) Adenocarcinoma of the prostate. Dirty necrosis content in the tumor cells
was observed in addition to the cribiform pattern of the cells. (B) High-power ﬁeld of
the prostatic tumor. Note the adenocarcinoma cell with dirty necrosis content.
Fig. 4. (A) Prostatic primary adenocarcinoma, positive for PSA stain. (B) Prostate tumor
specimen from the present case, negative for PSA stain. PSA ¼ prostate-speciﬁc
antigen.specimens (Fig. 5). Mucin is a marker of gastric adenocarcinoma.5e7
Based on the clinical history and immunohistochemical character-
istics of the specimens from the present case, the patient was
diagnosed as having metastatic prostatic adenocarcinoma derived
from a primary gastric adenocarcinoma.
Much has been reported regarding the treatment of metastatic
nodules that present in patients with urological malignancies. Most
studies suggest that treatment should be directed at the more
aggressive lesion ﬁrst, which would improve the overall survival
rate, and allow a better response to the therapy for the secondary
lesion.8
In conclusion, secondary prostatic neoplasms are rare, and most
reports of these lesions are based on autopsy ﬁndings or accidental
intraoperative ﬁndings. Presently, PSA stains are not routinely
performed for every transurethral prostate resection pathology
section. In the present case, adenocarcinoma was proven from the
pathology section, combined with the detection of other advanced
metastases (bone or liver). However, the serum PSA was nearly
normal, or only slightly elevated. When a secondary prostatic
adenocarcinoma is being considered, a PSA stain should be per-
formed by the pathologist. In this case, the presence of a malignant
Fig. 5. Mucin stain of prostatic tumor, positive in cytoplasm (arrows).
Y.-J. Ni et al. / Urological Science 24 (2013) 108e111 111prostatic neoplasm, combined with negative PSA-staining of the
pathology section, led to further investigation and the determina-
tion of the correct diagnosis of a distant primary lesion. Mucin was
used as a speciﬁc immunohistochemical marker of gastric adeno-
carcinoma. This information was important for the subsequent
therapeutic decisions. In this case, immunohistochemical staining
for speciﬁc markers was performed to differentiate the origin of the
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